Breast Cancer Outcomes After Diagnosis of Hormone-positive Breast Cancer and Subsequent Pregnancy in the Tamoxifen Era.

about

Motherhood after breast cancer: can we balance fertility preservation and cancer treatment? A narrative review of the literature

P2860

Q57107180-28C45050-4634-4BD1-B154-D18D98408159

P2860

Breast Cancer Outcomes After Diagnosis of Hormone-positive Breast Cancer and Subsequent Pregnancy in the Tamoxifen Era.

Item

http://www.wikidata.org/entity/Q38759021

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Breast Cancer Outcomes After D ...... regnancy in the Tamoxifen Era.

@en

type

Item

label

Breast Cancer Outcomes After D ...... regnancy in the Tamoxifen Era.

@en

prefLabel

Breast Cancer Outcomes After D ...... regnancy in the Tamoxifen Era.

@en

P1476

Breast Cancer Outcomes After D ...... regnancy in the Tamoxifen Era.

@en

P2093

Alfred Rademaker

http://www.w3.org/2001/XMLSchema#string

Lauren Nye

http://www.w3.org/2001/XMLSchema#string

William J Gradishar

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Breast cancer in young women: poor survival despite intensive treatment.

Gene expression patterns in the human breast after pregnancy.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Adjuvant ovarian suppression in premenopausal breast cancer.

Pregnancy after breast cancer: population based study.

Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.

Mammary developmental fate and breast cancer risk.

Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

P304

e185-e189

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CLBC.2016.12.014

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28185739

http://www.w3.org/2001/XMLSchema#string

P932

5482759

http://www.w3.org/2001/XMLSchema#string

Breast Cancer Outcomes After Diagnosis of Hormone-positive Breast Cancer and Subsequent Pregnancy in the Tamoxifen Era.

about

P2860

P2860

Breast Cancer Outcomes After Diagnosis of Hormone-positive Breast Cancer and Subsequent Pregnancy in the Tamoxifen Era.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932